Matt Kaplan

Matt Kaplan

Director/Board Member presso NUVECTIS PHARMA, INC.

Patrimonio netto: 440 832 $ in data 31/03/2024

56 anni
Finance
Consumer Services

Profilo

Mr. Matt L.
Kaplan
is a Managing Director & Head of Equity Research at Ladenburg Thalmann & Co., Inc. He has over 14 years of experience as a biotechnology analyst.
His current research focus is therapeutic companies, cardiovascular, and drug delivery.
Prior to joining Ladenburg Thalmann, he was a Partner and the Director of Healthcare Research with Punk, Ziegel & Company.
Previously, he was a Senior Biotechnology Analyst at Evolution Capital and a Director of The Life Sciences Group at The Carson Group.
Before joining The Carson Group and Evolution Capital, Mr. Kaplan had six years of experience as a Research Associate with the Albert Einstein College of Medicine/Montefiore Hospital Department of Cardiology.
Mr. Kaplan received his bachelor’s degree in Biology from the University of Michigan and studied Cellular and Molecular Biology at Columbia University.

Partecipazioni note in società pubbliche

SocietàDataNumero di azioniValorizzazioneData di valutazione
16/06/2023 53 760 ( 0.30% ) 440 832 $ 31/03/2024

Posizioni attive di Matt Kaplan

SocietàPosizioneInizio
NUVECTIS PHARMA, INC. Director/Board Member 01/09/2021
Director of Research - Equity 02/05/2008
Tutte le posizioni attive di Matt Kaplan

Precedenti posizioni note di Matt Kaplan

SocietàPosizioneFine
Analyst-Equity 01/05/2008
Corporate Officer/Principal 01/11/2003
Albert Einstein College of Medicine, Inc. Corporate Officer/Principal -
Vedi nel dettaglio l'esperienza di Matt Kaplan

Formazione di Matt Kaplan

University of Michigan Undergraduate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Matt Kaplan

Relazioni

69

Relazioni di 1° grado

6

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Aziende private4

Finance

Finance

Finance

Nuvectis Pharma, Inc.

Vedi le connessioni aziendali